Genitourinary
Bladder:
IRB #H-25192/RTOG #R0524: A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab with Daily Irradiation or Paclitaxel Alone With Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer (temp closure)
NCCN/IRB #H-27597: Phase II Randomized Trial of Gemcitabine and Cisplatin with or without Cetuximab in Patients with Urothelial Carcinoma
Prostate:
IRB #H-26662: Prostate Cancer and Vitamin D Therapy: Randomized Clinical Trial to Determine the Effect of Vitamin D3 from UVB Radiation and Supplements on Rising PSA Levels in Patients with Noncastrate Biochemical Failure
Prostate – High Risk:
IRB #2008-004C/RTOG #R0534: A Phase III Trial Of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy (SPORT) In Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy
IRB #H-27569/RTOG #R0621: Adjuvant 3DCRT/IMRT in Combination with Androgen Suppression and Docetaxel for High Risk Prostate Cancer Patients Post-Prostatectomy: A Phase II Trial
Prostate – Metastatic:
IRB #2005-051C/CTSU #C90202: A Randomized, Double-Blind, Placebo-Controlled Phase III Study of Early versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone
CIRB #2008-035C/SWOG #S0421: Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer
CIRB #2008-037C/CTSU #E3805: CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
Renal Cell:
IRB #2006-034C/CTSU #E2805: ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
